Rewards
Some stock data isn't available right now.

Intellia Therapeutics, Inc (NTLA)

Underlying price

$10.14

+6.61% last session

Stock stats

$1.40B
$9.52
$9.34
$9.33 – $10.38
$8.08 – $18.48
10.8M
5.06M
-
-
-$3.35
-
1.79

Analysts & earnings

Analyst ratings

Hold, 3.25 on a scale from 1, strong sell, to 5, strong buy
  • 1 Strong buy
  • 9 Buy
  • 6 Hold
  • 2 Sell
  • 2 Strong sell
$22.78+124.46%
Today
$10.14
Target
$22.78

Earnings per share

Beat estimates 2 of last 4

  • Estimate
  • Actual
  • Feb '26: actual -$0.83, estimate -$0.99
  • May '26: actual -$0.81, estimate -$0.9
  • Aug '26: actual -$0.8, estimate -$0.8
  • Nov '26: actual -$0.91, estimate -$0.82

About Intellia Therapeutics, Inc

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Ticker
NTLA
Asset class
Equity
Tokenized by
0 issuers
Sector
Healthcare
Industry
In Vitro & In Vivo Diagnostic Substances
Employees
377